# Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy

> **NCT07098481** · PHASE4 · NOT_YET_RECRUITING · sponsor: **ANRS, Emerging Infectious Diseases** · enrollment: 576 (estimated)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** ACCESS+ strategy Epclusa 400/100 Oral Tablet
- **DRUG:** ACCESS+ Strategy Vosevi 400/100/100 Oral Tablet
- **DRUG:** Standard Strategy Vosevi 400/100/100 Oral Tablet
- **DRUG:** Standard Strategy Epclusa 400/100 Oral Tablet

## Key facts

- **NCT ID:** NCT07098481
- **Lead sponsor:** ANRS, Emerging Infectious Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-09-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 576 (ESTIMATED)
- **Last updated:** 2025-08-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07098481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07098481, "Access to Hepatitis C Treatment in Cameroon: Comparison of a Simplified Test and Treat Strategy to a Standard Strategy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07098481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*